Striving to Quit-Wisconsin Tobacco Quit Line

Striving to Quit: Wisconsin Tobacco Quit Line Tobacco Cessation Research

This study is designed to test the hypotheses that incentives can increase both participation in smoking cessation treatment and resulting cessation rates when they are offered to Medicaid BadgerCare Plus members.

Study Overview

• Status: Withdrawn
• Conditions: Smoking; Smoking Cessation; Nicotine Dependence
• Intervention / Treatment: Behavioral: Attendance incentive; Behavioral: Incentives for abstinence and treatment engagement

Detailed Description

Aim 1: To determine the extent to which contingent financial "treatment incentives" (i.e., incentives for biochemical verification visits, treatment engagement, and abstinence) versus "attendance incentives" (i.e., incentives for only attending the biochemical verification visits), increase rates of smoking cessation . Participants will be BadgerCare Plus tobacco users who enroll in Wisconsin Tobacco Quit Line (WTQL) services.

Aim 2: To determine the extent to which treatment incentives vs. attendance incentives increase rates of engagement in smoking cessation treatment through the WTQL when offered to BadgerCare Plus members who smoke.

Aim 3: To determine the cost-effectiveness of the smoking cessation program when paired with treatment incentives and when paired with attendance incentives.

Aim 4: To identify moderating and mediational effects regarding the clinical benefit of incentivized smoking treatment

Aim 5: To determine the reach of an incentivized smoking cessation treatment that depends upon primary care clinic staff, a fax-to-quit referral mechanism and a state quit line.

• Study Type: Interventional
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• enrollment in Wisconsin Medicaid (BadgerCare Plus)
• resides in study area (one of 25 counties)
• member of participating HMOs
• 18 or older
• English speaking
• has smoked daily (at least 5 cigarettes each day) over the last week
• willingness to attend visits at his/her PCC (primary care clinic) every 6 months (3 times over a 12 month period), provide urine samples, and complete follow-up phone calls
• willingness to inform the WTQL as to any change in address, phone number, clinic attended, or health plan.

Exclusion Criteria:

• not enrolled in Wisconsin Medicaid (BadgerCare Plus)
• not reside in study area
• not a member participating HMOs
• less than 18 years of age
• not English speaking
• does not smoke daily (at least 5 cigarettes each day) over the last week
• not willing to attend visits at his/her PCC (primary care clinic) every 6 months (3 times over a 12 month period), provide urine samples, and complete follow-up phone calls.
• not willing to inform the WTQL as to any change in address, phone number, clinic attended, or health plan.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment incentives; Incentives for biochemical verification visits, treatment engagement, and abstinence	Behavioral: Incentives for abstinence and treatment engagement; Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
Active Comparator: Attendance incentive; Incentives for only attending the biochemical verification visits	Behavioral: Attendance incentive; Attendance Incentives - incentives for only attending the biochemical verification visits

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Abstinence from smoking	The data will be the biochemically confirmed reports of abstinence for the past 7 days (i.e., 7-day point-prevalence abstinence)	Measured 6 months after enrollment at follow-up assessment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Engagement in treatment	The primary analyses will compare number of calls completed	Measured 12 months after enrollment at follow-up assessment
Cost-effectiveness	The primary analysis will contrast the incremental costs of the treatment vs. attendance conditions by computing the Incremental Cost-Effectiveness Ratio (ICER) with regard to attaining 6-month abstinence.	Measured 12 months after enrollment

Collaborators and Investigators

• Sponsor: University of Wisconsin, Madison
• Investigators: Principal Investigator: Timothy B Baker, PhD, University of Wisconsin, Madison

Study record dates

Study Major Dates

• Study Start: September 1, 2012
• Primary Completion (Anticipated): March 1, 2013
• Study Completion (Actual): March 1, 2013

Study Registration Dates

• First Submitted: March 30, 2012
• First Submitted That Met QC Criteria: March 30, 2012
• First Posted (Estimate): April 3, 2012

Study Record Updates

• Last Update Posted (Estimate): December 6, 2016
• Last Update Submitted That Met QC Criteria: December 5, 2016
• Last Verified: December 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders; Tobacco Use Disorder
• Other Study ID Numbers: 2012-0198

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES